Abstract 3690
Background
With the success of immunotherapy in various solid cancers, the expression of programmed death-ligand 1 (PD-L1) in cancer cells has been attracting attention. The aim of this study was to analyze PD-L1 expression in resected UPS and evaluate its clinical impact.
Methods
All consecutive patients who were treated with UPS in Asan Medical Center, between January 1995 and December 2016, were retrospectively reviewed. PD-L1 staining was performed using SP263 antibody on their archived tissues. PD-L1 H-score was calculated by intensity (0-3) multiplied by proportion (0-100).
Results
A total of 176 patients with localized UPS who underwent curative-intent surgical resection were included in this study. There were 104 males (59.1%) and 72 females (40.9%), and the median age of patients was 59 years at the time of diagnosis. The most frequently involved primary site was extremities (84/176, 47.7%), followed by abdomen and pelvis (46/176, 26.1%), thorax (29/176, 16.5%), and head and neck (17/176, 9.7%). The PD-L1 analysis was available on slides from 114 (64.8%) patients and PD-L1 expression was observed in 83 (72.8%) cases. Intensity of staining varied between weak (44/83, 53.0%), intermediate (29/83, 34.9%), strong (10/83, 12.0%). Distribution of PD-L1 expression using different cut-off values were as follows: ≥1%: 83/114 (72.8%); ≥5%: 79/114 (69.3%); ≥10%: 52/114 (45.6%); ≥50%: 20/114 (17.5%). The 5-year disease free survival (DFS) rate seemed to be better in patients with PD-L1 positive than in patients with PD-L1 negative (56.5% vs 41.9%), but no statistical significant was observed (p = 0.183). There was a trend for better 5-year DFS rate with higher proportion of PD-L1 or higher PD-L1 H-score (proportion: 0% vs 1-49% vs ≥ 50, 41.9% vs 52.9% vs 70.1%, p = 0.098; H-score: 0 vs 1-100 vs ≥ 101, 41.9% vs 53.1% vs 75.7%, p = 0.087) without statistical singnificance.
Conclusions
In this study, PD-L1 protein expression was seen in substantial cases of resected UPS and it appeared to be a positive prognostic biomarker for longer DFS, although not statistically demonstrated. Further studies are needed comprehensively understand the impact of immune repertoire in UPS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2490 - Gender effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of anamorelin (ANAM) in healthy volunteers and cancer patients with cachexia
Presenter: Stein Kaasa
Session: Poster Display session 1
Resources:
Abstract
4294 - The Patient Voice: An Irish Survey of Nutrition Attitudes & Access to Dietetic Care Throughout the Cancer Journey
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
1925 - Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients
Presenter: Claudio Chini
Session: Poster Display session 1
Resources:
Abstract
4701 - Treatment-related adverse events and tolerability in patients with advanced non-squamous non-small cell lung cancer treated with first-line checkpoint inhibitors in combination with chemotherapy
Presenter: Ruth D'cunha
Session: Poster Display session 1
Resources:
Abstract
2985 - Clinical utility of a systematic toxicity assessment form (STAF) in patients with breast cancer receiving adjuvant or neoadjuvant therapy.
Presenter: Jwa Hoon Kim
Session: Poster Display session 1
Resources:
Abstract
2358 - Physicians’ satisfaction with Health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients.
Presenter: Guillaume Mouillet
Session: Poster Display session 1
Resources:
Abstract
5172 - Predictors of Survival in Patients with Incurable Cancer
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
2281 - Patients and Physicians' Satisfaction with Telemedicine (TM) in Cancer Care and Factors that Correlate with a Positive Patient’s Experience
Presenter: Hurria Gondal
Session: Poster Display session 1
Resources:
Abstract
2193 - Adherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: real-world insights from practicing European physicians
Presenter: Alex Rider
Session: Poster Display session 1
Resources:
Abstract
2200 - Use of skeletal-related events preventive agents in patients with solid tumours and bone metastases in central Denmark
Presenter: Anders Boysen
Session: Poster Display session 1
Resources:
Abstract